Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KDEV.ST
- Price
- 0.85
- Stock movement up
- +0.00 (0.47%)
- Company name
- Karolinska Development AB ser. B
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 227.19M
- Ent value
- 208.52M
- Price/Sales
- 93.07
- Price/Book
- 0.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -46.94%
- 1 year return
- -45.51%
- 3 year return
- -37.41%
- 5 year return
- -21.40%
- 10 year return
- -21.92%
Last updated: 2025-04-15
DIVIDENDS
KDEV.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 93.07 |
| Price to Book | 0.19 |
| EV to Sales | 85.42 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 267.28M |
| EPS (TTM) | -0.11 |
| FCF per share (TTM) | -0.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.44M |
| Gross profit (TTM) | 2.52M |
| Operating income (TTM) | -35.76M |
| Net income (TTM) | -28.53M |
| EPS (TTM) | -0.11 |
| EPS (1y forward) | -0.10 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 103.28% |
| Operating margin (TTM) | -1464.85% |
| Profit margin (TTM) | -1168.66% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 29.32M |
| Net receivables | 0.00 |
| Total current assets | 43.21M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.23B |
| Accounts payable | 1.16M |
| Short/Current long term debt | 2.35M |
| Total current liabilities | 10.65M |
| Total liabilities | 10.65M |
| Shareholder's equity | 1.22B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -26.34M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -26.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -2.34% |
| Return on Assets | -2.32% |
| Return on Invested Capital | -2.33% |
| Cash Return on Invested Capital | -2.15% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.89 |
| Daily high | 0.89 |
| Daily low | 0.83 |
| Daily Volume | 258K |
| All-time high | 34.89 |
| 1y analyst estimate | 2.40 |
| Beta | 0.19 |
| EPS (TTM) | -0.11 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 24 Apr 2025 |
Downside potential
Loading...
Downside potential data
| KDEV.ST | S&P500 | |
| Current price drop from All-time high | -97.56% | -12.04% |
| Highest price drop | -97.65% | -56.47% |
| Date of highest drop | 9 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -75.51% | -11.07% |
| Avg time to new high | 1762 days | 12 days |
| Max time to new high | 3522 days | 1805 days |
COMPANY DETAILS
Marketcap
227.19M
Marketcap category
Small-cap
Description
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
Employees
8
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Annual General Meeting, on Thursday May 15, 2025, at 3:00 p.m...
April 7, 2025
STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota rem...
April 1, 2025
STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition presents recent preclinical data showing that golexa...
April 1, 2025
STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024. The report is now available to download at www.karolinskad...
March 21, 2025
STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinic...
March 18, 2025
STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inot...
March 13, 2025
STOCKHOLM, SWEDEN – March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug cand...
March 12, 2025
STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the GOA...
February 25, 2025
STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacter...
February 18, 2025
STOCKHOLM – 14 February 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stro...
February 14, 2025
Next page